AUTHOR=Hu Shuang , Lian Pan-pan , Hu Ying , Zhu Xing-yu , Jiang Shao-wei , Ma Qiang , Li Liang-yun , Yang Jun-fa , Yang Li , Guo Hai-yue , Zhou Hong , Yang Chen-chen , Meng Xiao-ming , Li Jun , Li Hai-wen , Xu Tao , Zhou Huan 

TITLE=The Role of IL-35 in the Pathophysiological Processes of Liver Disease

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 11 - 2020

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.569575

DOI=10.3389/fphar.2020.569575

ISSN=1663-9812

ABSTRACT=It is known that liver diseases have several characteristics of massive lipid accumulation and lipid metabolic disorder, and are divided into inflammation, liver fibrosis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in patients. Interleukin (IL)-35, a new-discovered cytokine, can protect the liver from the environmental attack by increasing the ratio of Tregs (T regulatory cells) which can increase the anti-inflammatory cytokines and inhibit the proliferation of immune cellular. Also, IL-35 played crucial function in the process of liver diseases thought immunosuppressive regulation. When liver injury and inflammation occurred, two opposite mechanism, pro-inflammatory and anti-inflammatory, were in relation to the ultimate formation of diseases. Some obvious advantages indicate that IL-35 could be seen as a new therapeutic target to control the progression of liver diseases, but its mechanism of function still needs further research.